Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 12835230)

1.

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.

Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J, Barlogie B, Shaughnessy JD Jr, Stewart AK.

Blood. 2003 Jul 15;102(2):772-3. No abstract available.

2.

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.

Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E.

Br J Haematol. 2015 Feb;168(4):507-10. doi: 10.1111/bjh.13171. Epub 2014 Oct 10.

3.

MMSET: role and therapeutic opportunities in multiple myeloma.

Xie Z, Chng WJ.

Biomed Res Int. 2014;2014:636514. doi: 10.1155/2014/636514. Epub 2014 Jul 1. Review.

4.

Haematological cancer: abnormal chromosomes forecast rapid disease progression in SMM.

Errico A.

Nat Rev Clin Oncol. 2013 Dec;10(12):671. doi: 10.1038/nrclinonc.2013.214. Epub 2013 Nov 12. No abstract available.

PMID:
24217203
5.

Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma.

Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H, Masaki A, Yoshida T, Mori F, Ito A, Yano H, Ri M, Kayukawa S, Kataoka T, Kusumoto S, Ishida T, Hayami Y, Hanamura I, Komatsu H, Inagaki H, Matsuda Y, Ueda R, Iida S.

Leuk Res. 2013 Dec;37(12):1648-55. doi: 10.1016/j.leukres.2013.09.026. Epub 2013 Oct 18.

PMID:
24210217
6.

Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.

Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R, Phillips L, Baker A, Shi CX, Schmidt J, Liang WS, Craig DW, Carpten JD, Stewart AK.

Br J Haematol. 2013 Jun;161(5):748-51. doi: 10.1111/bjh.12291. Epub 2013 Mar 11. No abstract available.

7.

Thyroid cancer cell line misidentification: an update.

Schweppe RE.

J Clin Endocrinol Metab. 2013 Mar;98(3):956-7. doi: 10.1210/jc.2012-4182. No abstract available.

8.

Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.

Martin LD, Harizanova J, Righolt CH, Zhu G, Mai S, Belch AR, Pilarski LM.

Genes Chromosomes Cancer. 2013 Jun;52(6):523-37. doi: 10.1002/gcc.22049. Epub 2013 Mar 5.

PMID:
23460268
9.

Darwinian evolution and tiding clones in multiple myeloma.

Bahlis NJ.

Blood. 2012 Aug 2;120(5):927-8. doi: 10.1182/blood-2012-06-430645.

10.

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, Ashworth A, Davies FE, Morgan GJ.

Blood. 2012 Aug 2;120(5):1077-86. doi: 10.1182/blood-2012-03-412981. Epub 2012 May 9.

11.

Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.

Nagy Z, Kajtár B, Jáksó P, Dávid M, Kosztolányi S, Hermesz J, Kereskai L, Pajor L, Alpár D.

Leuk Res. 2011 Aug;35(8):1114-6. doi: 10.1016/j.leukres.2011.02.010. Epub 2011 Mar 5.

PMID:
21377730
12.

Deciding on the therapy of multiple myeloma using genetic risk stratification.

Gertz MA.

Leuk Lymphoma. 2011 Feb;52(2):157-8. doi: 10.3109/10428194.2010.542601. Epub 2011 Jan 24. No abstract available.

PMID:
21261501
13.

Clinical and biological features of t(4;14) multiple myeloma: a prospective study.

Karlin L, Soulier J, Chandesris O, Choquet S, Belhadj K, Macro M, Bouscary D, Porcher R, Ghez D, Malphettes M, Asli B, Brouet JC, Bories JC, Hermine O, Fermand JP, Arnulf B.

Leuk Lymphoma. 2011 Feb;52(2):238-46. doi: 10.3109/10428194.2010.537795. Epub 2011 Jan 24.

PMID:
21261498
14.

FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.

Quintero-Rivera F, El-Sabbagh Badr R, Rao PN.

Cancer Genet Cytogenet. 2009 Nov;195(1):92-3. doi: 10.1016/j.cancergencyto.2009.06.018. No abstract available.

PMID:
19837276
15.

Spontaneous remission in a patient with t(4;14) translocation multiple myeloma.

Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, Zeng S, Fonseca R, Kukreti V.

J Clin Oncol. 2009 Nov 20;27(33):e194-7. doi: 10.1200/JCO.2009.22.0392. Epub 2009 Oct 5. Review. No abstract available.

PMID:
19805681
16.

FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).

Våtsveen TK, Brenne AT, Dai HY, Waage A, Sundan A, Børset M.

Eur J Haematol. 2009 Nov;83(5):471-6. doi: 10.1111/j.1600-0609.2009.01312.x. Epub 2009 Jul 6.

PMID:
19594619
18.

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.

Bisping G, Wenning D, Kropff M, Gustavus D, Müller-Tidow C, Stelljes M, Munzert G, Hilberg F, Roth GJ, Stefanic M, Volpert S, Mesters RM, Berdel WE, Kienast J.

Clin Cancer Res. 2009 Jan 15;15(2):520-31. doi: 10.1158/1078-0432.CCR-08-1612.

19.
20.

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH.

Blood. 2008 Jan 15;111(2):856-64. Epub 2007 Oct 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk